Dyne Therapeutics Inc - Asset Resilience Ratio
Dyne Therapeutics Inc (DYN) has an Asset Resilience Ratio of 20.28% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2025)
This chart shows how Dyne Therapeutics Inc's Asset Resilience Ratio has changed over time. Check DYN PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Dyne Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Dyne Therapeutics Inc market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $219.05 Million | 20.28% |
| Total Liquid Assets | $219.05 Million | 20.28% |
Asset Resilience Insights
- Good Liquidity Position: Dyne Therapeutics Inc maintains a healthy 20.28% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Dyne Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Dyne Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Akero Therapeutics Inc
NASDAQ:AKRO |
Biotechnology | 55.87% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Zealand Pharma A/S
CO:ZEAL |
Biotechnology | 63.98% |
|
Verona Pharma PLC ADR
NASDAQ:VRNA |
Biotechnology | 0.00% |
|
Immunitybio Inc
NASDAQ:IBRX |
Biotechnology | 38.07% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Annual Asset Resilience Ratio for Dyne Therapeutics Inc (2007–2025)
The table below shows the annual Asset Resilience Ratio data for Dyne Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 18.30% | $217.19 Million | $1.19 Billion | -11.62pp |
| 2024-12-31 | 29.92% | $206.82 Million | $691.23 Million | +29.03pp |
| 2023-12-31 | 0.89% | $1.47 Million | $165.08 Million | -26.48pp |
| 2022-12-31 | 27.38% | $83.86 Million | $306.32 Million | -13.91pp |
| 2021-12-31 | 41.29% | $175.75 Million | $425.66 Million | +28.70pp |
| 2020-12-31 | 12.58% | $44.46 Million | $353.33 Million | +12.31pp |
| 2017-12-31 | 0.27% | $32.00 Million | $11.77 Billion | -0.72pp |
| 2016-12-31 | 1.00% | $130.00 Million | $13.05 Billion | +0.13pp |
| 2015-12-31 | 0.87% | $100.00 Million | $11.54 Billion | +0.17pp |
| 2014-12-31 | 0.69% | $78.00 Million | $11.23 Billion | +0.22pp |
| 2013-12-31 | 0.47% | $25.00 Million | $5.29 Billion | +0.19pp |
| 2012-12-31 | 0.29% | $13.00 Million | $4.54 Billion | -1.39pp |
| 2011-12-31 | 1.67% | $69.00 Million | $4.13 Billion | +0.61pp |
| 2010-12-31 | 1.06% | $106.00 Million | $10.01 Billion | +0.35pp |
| 2009-12-31 | 0.71% | $78.00 Million | $10.95 Billion | +0.10pp |
| 2008-12-31 | 0.61% | $87.00 Million | $14.21 Billion | -0.17pp |
| 2007-12-31 | 0.79% | $104.00 Million | $13.22 Billion | -- |
About Dyne Therapeutics Inc
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal mus… Read more